The absorption of doxorubicin and mitomycin C in perioperative instillation. An experimental and clinical study

European Urology
|January 1, 1985
PubMed

Insights

Doxorubicin and mitomycin C showed poor absorption through rabbit bladder walls. Clinical findings of minimal side effects align with these experimental results, suggesting limited systemic exposure.

Area of Science:

  • Pharmacology
  • Urology
  • Oncology

Background:

  • Systemic absorption of intravesical chemotherapy can lead to toxicity.
  • Doxorubicin (ADM) and mitomycin C (MMC) are used in bladder cancer treatment.
  • Understanding drug absorption is crucial for optimizing treatment and minimizing side effects.

Purpose of the Study:

  • To evaluate the absorption of doxorubicin (ADM) and mitomycin C (MMC) through the rabbit bladder wall.
  • To compare absorption in intact versus damaged bladder tissues.
  • To correlate experimental findings with preliminary clinical observations.

Main Methods:

  • Pharmacokinetic study using rabbits.
  • Administration of ADM and MMC intravesically.
  • Analysis of drug levels in bloodstream and bladder tissue.
  • Assessment of bladder wall integrity.

Main Results:

  • Neither ADM nor MMC were significantly absorbed into the bloodstream from the rabbit bladder.
  • Absorption was minimal regardless of whether the bladder wall was intact or damaged.
  • Experimental data supports preliminary clinical findings.

Conclusions:

  • Intravesical doxorubicin and mitomycin C exhibit low systemic absorption in rabbits.
  • This suggests a favorable safety profile for intravesical administration, with limited risk of systemic toxicity.
  • Further clinical studies are warranted to confirm these findings in human patients.